# NextCure, Inc.: financial statements, quarterly

NXTC · Nasdaq · CIK 1661059 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/nxtc.md) · [Financials](/companies/nxtc/financials.md) · [Filings](/companies/nxtc/filings.md) · [Insiders](/companies/nxtc/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/nxtc/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [11.0](/filings/0001558370-24-014869.md) | [11.8 d](/filings/0001558370-25-002402.md) | [11.4](/filings/0001558370-25-006111.md) | [12.4](/filings/0001558370-25-010782.md) | [8.8](/filings/0001104659-25-107036.md) | [8.9 d](/filings/0001104659-26-024137.md) | [7.9](/filings/0001104659-26-057187.md) | [24.1](/filings/0001104659-26-092050.md) | [6.1](/filings/0001104659-25-107036.md) | [6.8 d](/filings/0001104659-26-024137.md) | [6.8](/filings/0001104659-26-057187.md) | [7.4](/filings/0001104659-26-092050.md) |
| Operating income | $m | [(15.6)](/filings/0001558370-24-014869.md) | [(15.8) d](/filings/0001558370-25-002402.md) | [(18.3)](/filings/0001558370-25-006111.md) | [(16.5)](/filings/0001558370-25-010782.md) | [(12.5)](/filings/0001104659-25-107036.md) | [(12.5) d](/filings/0001104659-26-024137.md) | [(11.6)](/filings/0001104659-26-057187.md) | [(27.3)](/filings/0001104659-26-092050.md) | [(8.9)](/filings/0001104659-25-107036.md) | [(9.8) d](/filings/0001104659-26-024137.md) | [(10.1)](/filings/0001104659-26-057187.md) | [(15.1)](/filings/0001104659-26-092050.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.0](/filings/0001558370-24-014869.md) | not reported | [0.0](/filings/0001558370-25-006111.md) | [0.0](/filings/0001558370-25-010782.md) | [0.0](/filings/0001104659-25-107036.md) | not reported | [0.0](/filings/0001104659-26-057187.md) | [0.0](/filings/0001104659-26-092050.md) | [0.0](/filings/0001104659-25-107036.md) | not reported | [0.0](/filings/0001104659-26-057187.md) | [0.0](/filings/0001104659-26-092050.md) |
| Net income | $m | [(14.3)](/filings/0001558370-24-014869.md) | [(14.5) d](/filings/0001558370-25-002402.md) | [(17.1)](/filings/0001104659-25-107036.md) | [(15.4)](/filings/0001104659-25-107036.md) | [(11.5)](/filings/0001104659-25-107036.md) | [(11.6) d](/filings/0001104659-26-024137.md) | [(11.0)](/filings/0001104659-26-092050.md) | [(26.8)](/filings/0001104659-26-092050.md) | [(8.6)](/filings/0001104659-25-107036.md) | [(9.4) d](/filings/0001104659-26-024137.md) | [(9.8)](/filings/0001104659-26-092050.md) | [(14.9)](/filings/0001104659-26-092050.md) |
| Diluted EPS | $ per share | [(0.51)](/filings/0001558370-24-014869.md) | not reported | [(0.61)](/filings/0001558370-25-006111.md) | [(6.61)](/filings/0001558370-25-010782.md) | [(4.95)](/filings/0001104659-25-107036.md) | not reported | [(4.70)](/filings/0001104659-26-057187.md) | [(11.29)](/filings/0001104659-26-092050.md) | [(3.22)](/filings/0001104659-25-107036.md) | not reported | [(1.87)](/filings/0001104659-26-057187.md) | [(2.80)](/filings/0001104659-26-092050.md) |
| Basic EPS | $ per share | [(0.51)](/filings/0001558370-24-014869.md) | not reported | [(0.61)](/filings/0001558370-25-006111.md) | [(6.61)](/filings/0001558370-25-010782.md) | [(4.95)](/filings/0001104659-25-107036.md) | not reported | [(4.70)](/filings/0001104659-26-057187.md) | [(11.29)](/filings/0001104659-26-092050.md) | [(3.22)](/filings/0001104659-25-107036.md) | not reported | [(1.87)](/filings/0001104659-26-057187.md) | [(2.80)](/filings/0001104659-26-092050.md) |

- Revenue: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [19.5](/filings/0001558370-23-017429.md) | [13.1](/filings/0001558370-25-002402.md) | [18.4](/filings/0001558370-24-006551.md) | [20.8](/filings/0001558370-24-010605.md) | [27.7](/filings/0001558370-24-014869.md) | [27.7](/filings/0001104659-26-024137.md) | [21.8](/filings/0001558370-25-006111.md) | [4.9](/filings/0001558370-25-010782.md) | [7.3](/filings/0001104659-25-107036.md) | [26.0](/filings/0001104659-26-092050.md) | [15.2](/filings/0001104659-26-057187.md) | [15.3](/filings/0001104659-26-092050.md) |
| Current assets | $m | [123](/filings/0001558370-23-017429.md) | [113](/filings/0001558370-25-002402.md) | [103](/filings/0001558370-24-006551.md) | [90.5](/filings/0001558370-24-010605.md) | [78.7](/filings/0001558370-24-014869.md) | [71.8](/filings/0001104659-26-024137.md) | [58.9](/filings/0001558370-25-006111.md) | [40.0](/filings/0001558370-25-010782.md) | [32.6](/filings/0001104659-25-107036.md) | [43.7](/filings/0001104659-26-092050.md) | [31.7](/filings/0001104659-26-057187.md) | [22.3](/filings/0001104659-26-092050.md) |
| Total assets | $m | [140](/filings/0001558370-23-017429.md) | [128](/filings/0001558370-25-002402.md) | [115](/filings/0001558370-24-006551.md) | [103](/filings/0001558370-24-010605.md) | [90.3](/filings/0001558370-24-014869.md) | [80.9](/filings/0001104659-26-024137.md) | [67.1](/filings/0001558370-25-006111.md) | [47.7](/filings/0001558370-25-010782.md) | [39.6](/filings/0001104659-25-107036.md) | [50.2](/filings/0001104659-26-092050.md) | [38.0](/filings/0001104659-26-057187.md) | [22.6](/filings/0001104659-26-092050.md) |
| Current liabilities | $m | [6.6](/filings/0001558370-23-017429.md) | [6.9](/filings/0001558370-25-002402.md) | [9.6](/filings/0001558370-24-006551.md) | [10.8](/filings/0001558370-24-010605.md) | [8.7](/filings/0001558370-24-014869.md) | [9.6](/filings/0001104659-26-024137.md) | [5.7](/filings/0001558370-25-006111.md) | [10.8](/filings/0001558370-25-010782.md) | [11.0](/filings/0001104659-25-107036.md) | [10.6](/filings/0001104659-26-092050.md) | [6.9](/filings/0001104659-26-057187.md) | [6.4](/filings/0001104659-26-092050.md) |
| Total liabilities | $m | [13.5](/filings/0001558370-23-017429.md) | [13.6](/filings/0001558370-25-002402.md) | [16.1](/filings/0001558370-24-006551.md) | [17.1](/filings/0001558370-24-010605.md) | [14.8](/filings/0001558370-24-014869.md) | [15.4](/filings/0001104659-26-024137.md) | [11.3](/filings/0001558370-25-006111.md) | [16.0](/filings/0001558370-25-010782.md) | [16.0](/filings/0001104659-25-107036.md) | [15.2](/filings/0001104659-26-092050.md) | [11.3](/filings/0001104659-26-057187.md) | [10.5](/filings/0001104659-26-092050.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [126](/filings/0001558370-24-014869.md) | [114](/filings/0001104659-26-024137.md) | [99.0](/filings/0001104659-25-107036.md) | [85.4](/filings/0001104659-25-107036.md) | [75.6](/filings/0001104659-25-107036.md) | [65.5](/filings/0001104659-26-092050.md) | [55.9](/filings/0001104659-26-092050.md) | [29.6](/filings/0001104659-26-092050.md) | [23.6](/filings/0001104659-25-107036.md) | [34.9](/filings/0001104659-26-092050.md) | [26.7](/filings/0001104659-26-092050.md) | [12.1](/filings/0001104659-26-092050.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(12.8) d](/filings/0001558370-24-014869.md) | [(10.7) d](/filings/0001558370-25-002402.md) | [(12.6)](/filings/0001558370-25-006111.md) | [(9.8) d](/filings/0001558370-25-010782.md) | [(11.5) d](/filings/0001104659-25-107036.md) | [(7.0) d](/filings/0001104659-26-024137.md) | [(13.0)](/filings/0001104659-26-057187.md) | [(22.7) d](/filings/0001104659-26-092050.md) | [(6.3) d](/filings/0001104659-25-107036.md) | [(7.6) d](/filings/0001104659-26-024137.md) | [(13.4)](/filings/0001104659-26-057187.md) | [(9.7) d](/filings/0001104659-26-092050.md) |
| Capital expenditure | $m | [0.3 d](/filings/0001558370-24-014869.md) | [0.0 d](/filings/0001558370-25-002402.md) | [0.0](/filings/0001558370-25-006111.md) | [0.3 d](/filings/0001558370-25-010782.md) | [0.2 d](/filings/0001104659-25-107036.md) | [(0.0) d](/filings/0001104659-26-024137.md) | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [27.7](/filings/0001558370-23-017429.md) | [27.8](/filings/0001558370-24-006551.md) | [27.8](/filings/0001558370-24-010605.md) | [27.8](/filings/0001558370-24-014869.md) | [27.9](/filings/0001558370-25-006111.md) | [2.3](/filings/0001558370-25-010782.md) | [2.3](/filings/0001104659-25-107036.md) | [2.3](/filings/0001104659-26-057187.md) | [2.4](/filings/0001104659-26-092050.md) | [2.7](/filings/0001104659-25-107036.md) | [5.2](/filings/0001104659-26-057187.md) | [5.3](/filings/0001104659-26-092050.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 4,577,359 at 2026-07-31, from the cover of the [10-Q filed 2026-08-06](/filings/0001104659-26-092050.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.